Wegovy to Semaglutide: What the Conversion Actually Means

If Wegovy is semaglutide, why do people look for a conversion?

The confusion is understandable. Several medicines share the same active ingredient but carry different brand names, different licensed indications, and different dose ladders. People often arrive at the search term "wegovy to semaglutide conversion" after seeing Ozempic discussed alongside Wegovy, or after a pharmacist mentioned the generic name on their prescription paperwork, and they want to check whether those are the same thing or not.

They are, at the molecular level. What differs is the authorised use. The NHS semaglutide medicines page makes the distinction plain: Wegovy is indicated for weight management; Ozempic is indicated for type 2 diabetes. Rybelsus, the original oral semaglutide, carries the same diabetes-only licence. A prescriber cannot simply swap one brand for another and call it weight-loss treatment, the licensed indication travels with the brand. That matters legally, clinically, and for your safety.

So the real questions people are trying to answer vary. Some want to know whether an Ozempic dose maps onto a Wegovy dose if they are switching, that is the territory covered in our guide to switching from Ozempic to Wegovy. Others want to understand how the new Wegovy tablet compares to the injection. Both are worth answering, which is what this page does.

How do the Wegovy injection doses sit alongside other semaglutide products?

The Wegovy injection titrates upward from a 0.25 mg starting dose, moving in roughly four-weekly steps through 0.5 mg, 1.0 mg, 1.7 mg, and 2.4 mg as the standard maintenance dose. The MHRA approved a higher 7.2 mg dose in early 2026, initially supplied as three 2.4 mg pens per week, then as a dedicated single-dose pen approved in April 2026 for adults with a BMI of 30 or above. Full details of the 7.2 mg pen approval are covered on our page on the new version of semaglutide.

Ozempic, by contrast, reaches a maximum of 2 mg weekly and is not approved above that for diabetes management. Its dose steps do not align precisely with Wegovy's titration steps, which is one reason a conversion chart for switching between them is more involved than simply matching numbers. If you are moving from Saxenda, a different weight-loss injection (liraglutide rather than semaglutide), our Saxenda to Wegovy conversion chart covers that route specifically.

The key practical point: a prescriber handles any dose-matching decision. The numbers on a chart online are context only. What you are actually prescribed depends on your current dose, how long you have been on it, your tolerance, and your clinical picture.

What about the Wegovy tablet, is the conversion from injection to pill straightforward?

Not straightforwardly, no. Oral semaglutide (the Wegovy tablet, approved by the MHRA on 11 June 2026 as the first oral GLP-1 medicine licensed in the UK for weight management) uses a completely separate dose schedule: 1.5 mg, 4 mg, 9 mg, rising to a 25 mg maintenance dose. Those numbers look very different from the injection's milligrams, and that is because absorption works differently when semaglutide is swallowed rather than injected. The tablet is co-formulated with an absorption enhancer, taken first thing in the morning on an empty stomach with a small amount of plain water, at least 30 minutes before food or other oral medicines.

According to the MHRA's approval, patients already established on the 2.4 mg weekly injection may be able to move directly to the 25 mg tablet, subject to clinical assessment. This is not a patient-led decision; a prescriber needs to review it. You can read more about how Wegovy works across both formulations, and our semaglutide overview compares the licensed forms side by side.

One thing the tablet changes, practically: no refrigeration. An injectable pen needs to live in the fridge; a Wegovy tablet does not. For people who travel frequently or simply find a daily tablet easier to fit into a routine, that is a meaningful difference, though the clinical suitability question still sits with a prescriber, not the logistics.

Does any of this affect whether you can get Wegovy privately?

Wegovy, in both injection and tablet form, is a prescription-only medicine. The eligibility criteria for private treatment broadly follow the licensed indications: adults with a BMI of 30 or above, or 27 or above with a weight-related condition such as high blood pressure, raised cholesterol, type 2 diabetes, or obstructive sleep apnoea. Lower BMI thresholds may apply for some ethnic backgrounds under UK clinical guidance. A prescriber at a registered UK pharmacy like nume reviews each case individually, no automated decisions.

Our guide on Wegovy eligibility criteria covers the full picture, including the BMI thresholds in detail. If you are weighing up treatment options more broadly, our weight-loss treatment overview sets out how the available medicines compare. And if cost is part of the decision, our Wegovy price guide explains what private treatment typically costs and what a legitimate price should include.

A note for anyone who has seen references to a "generic semaglutide" or compounded versions: the MHRA does not consider compounded semaglutide equivalent to a licensed product. Our page on the Wegovy generic question addresses this directly. Buying semaglutide from any source that does not require a valid prescription is not a safe route, and the MHRA has seized millions of doses of illicitly traded weight-loss medicines in the UK. The right route is a registered pharmacy, a qualified prescriber, and a medicine from the licensed supply chain.

If you would like a prescriber to assess your suitability for Wegovy, the consultation is free and reviewed the same day by a qualified clinician. Start your free consultation and get a clinical answer, not a chart.